pDONR223-TYK2 Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-TYK2
| Articles |
|---|
| Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Waanders E, Scheijen B, Jongmans MC, Venselaar H, van Reijmersdal SV, van Dijk AH, Pastorczak A, Weren RD, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden VH, Gruhn B, Hoogerbrugge PM, van Dongen JJ, Geurts van Kessel A, van Leeuwen FN, Kuiper RP. Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.277. PubMed |
| STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling. Xiang Q, Yang Z, Nicholas J. PLoS Pathog. 2022 Jul 1;18(7):e1010676. doi: 10.1371/journal.ppat.1010676. eCollection 2022 Jul. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.